Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation

http://www.therapeuticsdaily.com/news/article.cfm?contentvalue=590533&contenttype=newsarchive&channelID=26

Comments are closed.